Omada is better funded than its digital health rival Livongo, but can it achieve a similar valuation?
In a time of unpredictable demand for its products, the diversified medtech is unafraid to acquire.
The newest player in corporate financing, Intuitive, intends to deploy its fund with surgical precision.
Setting its sights on the screening setting, Exact aims to be a major liquid biopsy player.
Antigen tests for Covid-19 can be useful if used in the right settings, but those settings are expensive.
Slower labs are to be paid less for Covid-19 tests, but will the move actually speed things up?
The new regulatory scheme poses problems – but also opportunities, in the shape of possible alignment with the US.